STAT+: A setback for Roche’s breast cancer drugSTAT+: A setback for Roche’s breast cancer drug
Wall Street’s verdict on Prasad, generic semaglutide’s new pricing, and other biotech news
GLP-1 Drugs and Bone Injury; ‘Fire-Breathing’ Teen Trend; Saunas’ Health Benefits?GLP-1 Drugs and Bone Injury; ‘Fire-Breathing’ Teen Trend; Saunas’ Health Benefits?
(MedPage Today) — Note that some links may require registration or subscription. GLP-1 receptor agonists may increase the risk of bone and tendon injuries along with conditions such as osteoporosis and gout, a retrospective study suggested. … (MedPage Today) — Note that some links may require registration or subscription. GLP-1 receptor agonists may increase Read More
STAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy salesSTAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales
Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug Wegovy. The Danish drugmaker said Monday that it’s dropping a lawsuit that claims Hims infringed on a key patent for its Wegovy products, and Hims Read More
Digital Microsteps as Scalable Adjuncts for Adults Using GLP-1 RAsDigital Microsteps as Scalable Adjuncts for Adults Using GLP-1 RAs
This randomized clinical trial evaluates whether digital behavior change prompts augmented with short videos increase expectations to adopt lifestyle behaviors in adults using glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This randomized clinical trial evaluates whether digital behavior change prompts augmented with short videos increase expectations to adopt lifestyle behaviors in adults using glucagon-like peptide-1 receptor Read More
Preventing breast cancer resistance to CDK4/6 inhibitors using genomic findingsPreventing breast cancer resistance to CDK4/6 inhibitors using genomic findings
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor’s genetic profile.
GLP-1 drugs linked to higher fracture risk, osteoporosis and gout, new studies suggestGLP-1 drugs linked to higher fracture risk, osteoporosis and gout, new studies suggest
GLP-1 medications such as Ozempic and Wegovy have transformed treatment for type 2 diabetes and obesity — but new research suggests doctors may need to pay closer attention to bone health, especially in older patients taking the drugs. Older adults with type 2 diabetes who started GLP-1s had an 11% higher risk of fragility fractures Read More
Study maps complex interplay between cells, metabolism, and immunity in breast cancer lymph node metastasisStudy maps complex interplay between cells, metabolism, and immunity in breast cancer lymph node metastasis
A recent integrative analysis of single-cell sequencing and single-cell spatial mapping of lymph node metastasis in breast cancer reveals novel mechanisms of the metabolic-immune interaction that drive the spread of breast cancer. The findings from the study in The American Journal of Pathology, offer novel insights into the characteristics of the metastatic tumor microenvironment, providing a foundation for targeted therapeutic strategies.
AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosisAAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Read More
Some patients keep weight off with fewer GLP-1 injections, study findsSome patients keep weight off with fewer GLP-1 injections, study finds
Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study. Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study.
How do GLP-1 agonists affect gene expression?How do GLP-1 agonists affect gene expression?
GLP-1s are building a reputation as “wonder drugs.” First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health. In addition to these surprising bonus benefits is the ability of GLP-1 drugs to improve pancreatic beta cell health. But how, exactly, Read More